Statements (58)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:acquisition |
gptkb:Stiefel_Laboratories
gptkb:Smith_Kline_Beecham |
| gptkbp:annual_report |
publishes annual reports
|
| gptkbp:ceo |
gptkb:Emma_Walmsley
|
| gptkbp:clinical_trial |
conducts clinical trials globally
invests in clinical research conducts Phase I to Phase III trials focuses on patient-centric clinical trials |
| gptkbp:collaboration |
with academic institutions
with healthcare organizations |
| gptkbp:collaborations |
forms research partnerships with universities
|
| gptkbp:community_engagement |
engages in community health initiatives
|
| gptkbp:conducts_research_on |
gptkb:Dr._Hal_Barron
|
| gptkbp:dividend_yield |
approximately 5% (2021)
|
| gptkbp:founded |
gptkb:2000
|
| gptkbp:headquarters |
gptkb:Brentford,_London
Brentford, London, England |
| gptkbp:healthcare |
works to improve healthcare access globally
|
| gptkbp:history |
formed from the merger of Glaxo Wellcome and Smith Kline Beecham
|
| https://www.w3.org/2000/01/rdf-schema#label |
Glaxo Smith Kline plc
|
| gptkbp:industry |
gptkb:pharmaceuticals
|
| gptkbp:innovation |
focuses on innovation in drug development
|
| gptkbp:invention |
holds numerous patents in pharmaceuticals
|
| gptkbp:investment |
provides investor relations information
|
| gptkbp:leadership |
led by a board of directors
|
| gptkbp:market_cap |
approximately £80 billion (2021)
|
| gptkbp:market_position |
operates in over 100 countries
|
| gptkbp:number_of_employees |
99,000 (2020)
|
| gptkbp:partnership |
gptkb:Pfizer
gptkb:Novartis |
| gptkbp:partnerships |
collaborates with biotech firms
|
| gptkbp:philanthropy |
GSK IMPACT Awards
GSK's Global Health Programs |
| gptkbp:products |
antibiotics
vaccines antidepressants |
| gptkbp:regulatory_compliance |
seeks regulatory approval for new drugs
|
| gptkbp:research_and_development |
significant investment in R& D
|
| gptkbp:research_focus |
oncology
central nervous system disorders infectious diseases immunology respiratory diseases |
| gptkbp:revenue |
£34.1 billion (2020)
|
| gptkbp:social_responsibility |
committed to corporate social responsibility
|
| gptkbp:stock_exchange |
gptkb:London_Stock_Exchange
|
| gptkbp:stock_symbol |
gptkb:GSK
|
| gptkbp:subsidiary |
gptkb:Vii_V_Healthcare
HIV therapeutics |
| gptkbp:supply_chain |
manages a global supply chain
|
| gptkbp:sustainability |
environmental initiatives
diversity and inclusion initiatives access to medicines |
| gptkbp:training |
provides employee training programs
|
| gptkbp:website |
gsk.com
|
| gptkbp:bfsParent |
gptkb:Glaxo_Smith_Kline
|
| gptkbp:bfsLayer |
5
|